{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-221538","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.839929+00:00","generated_at":"2026-05-17T05:23:04.508637+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Larimar reports positive nomlabofusp data; all 6-month patients reach carrier-level FXN","bullets":["10/10 participants at 6 months achieved skin FXN >50% of healthy volunteer median (asymptomatic carrier levels).","Directional improvement in mFARS, FARS-ADL, 9-HPT, MFIS vs worsening in natural history cohort after 1 year.","Anaphylaxis occurred in 7 participants (all within first 6 weeks); starting dose regimen modified; FDA agreed.","BLA submission seeking accelerated approval for nomlabofusp expected in Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-221538","json":"https://secwatch.observer/filing/0001193125-25-221538.json","markdown":"https://secwatch.observer/filing/0001193125-25-221538.md","text":"https://secwatch.observer/filing/0001193125-25-221538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000119312525221538/0001193125-25-221538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000119312525221538/d24800d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:23:04.508637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}